We are live on ! Find out more

Heron Therapeutics

HRTX

Market cap $61.3M

0.3228 USD

+0.0046

1.45%

At close Updated Aug 24, 4:00 PM EDT

Pre-market

After hours

0.3250

+0.0022

0.68%

1 day

1.45%

5 days

4.13%

1 month

-29.18%

3 months

-63.46%

6 months

-70.39%

Year to date

-74.38%

1 year

-76.61%

5 years

-97.19%

10 years

-98.37%

About: Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Employees: 128

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 50%

Negative 50%

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations.

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Zacks Investment Research

New Strong Sell Stocks for July 15th

BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.

New Strong Sell Stocks for July 15th

U.S. District Court Issues Decision Regarding CINVANTI® Patents

CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.

Heron Therapeutics Q1 Earnings Call Highlights

Zacks Investment Research

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™